Emerging nanotechnology-based therapies in the treatment of diabetes: recent developments and future opinion

The advent of nanotechnology has transformed drug development, providing innovative solutions for designing and administering therapeutic agents with improved accuracy and efficacy in managing diabetes. This review aims to critically analyze the progress, mechanisms, and therapeutic uses of nanotechnology-based treatments against the diseases.

The application of nanotechnology in diabetes therapy represents a significant breakthrough in contemporary medicine. By facilitating precise, controlled, and responsive drug delivery systems, nanotechnology-based treatments present considerable advantages over traditional methods.

Glipizide sustained-release nanoparticles, repaglinide-loaded polymeric systems, and metformin-loaded alginate nanocapsules are just a few of the nanoformulations that have shown markedly improved pharmacokinetics and therapeutic efficacy in preclinical models. In addition to lowering the frequency of doses, these nano-delivery methods extended glycemic control and enhanced oral bioavailability. Niosomes and solid lipid nanoparticles are two examples of formulations that have demonstrated promise in overcoming physiological obstacles such poor intestinal absorption and enzymatic breakdown. When taken as a whole, these results highlight how revolutionary nanotechnology can be for managing diabetes.

The development of new nano formulations shows great promise in preventing hyperglycemia and improving diabetes management; however, challenges, such as biocompatibility, scalability, and regulatory approval pose substantial obstacles to clinical implementation. Nevertheless, the expanding roles of nanotechnology in diabetes therapy present transformative opportunities, highlighting the necessity for ongoing interdisciplinary research to refine these nanotherapeutics for safe and effective clinical applications.